Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESGCT 2021 | ESGCT 2021 highlights: AAV vector capsid modification for CNS disorders

Michael Hocquemiller, PhD, Lysogene, Paris, France, discuses his highlights from the 2021 European Society of Gene & Cell Therapy (ESGCT) Congress. He notes that ongoing research into adeno-associated virus (AAV) vector capsid modification is of particular importance in gene therapy for central nervous system (CNS) disorders. The ability to enhance the tropism of AAV vectors could allow more efficient targeting of the CNS following intravenous injection, thus allowing the administration of lower vector doses which would reduce challenges associated with toxicity and vector manufacturing. This interview took place at the ESGCT Virtual Congress 2021.